<?xml version="1.0" encoding="UTF-8"?>
<search_results count="6">
  <query>epclusa</query>
<!-- Additional study fields may be added over time -->  <study rank="1">
    <nct_id>NCT02822794</nct_id>
    <title>Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>20 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>110</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Allocation: Randomized</study_design>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Parallel Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-3921</other_id>
    </other_ids>
    <first_received>June 30, 2016</first_received>
    <start_date>July 2016</start_date>
    <completion_date>November 2017</completion_date>
    <last_updated>August 26, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>August 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Proportion of Participants With SVR at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of Participants With HCV RNA &lt; LLOQ By Visit While on Study Treatment</outcome_measure>
      <outcome_measure>Change From Baseline in HCV RNA</outcome_measure>
      <outcome_measure>Proportion of Participants With Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Japan</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02822794</url>
  </study>
  <study rank="2">
    <nct_id>NCT02781571</nct_id>
    <title>Sofosbuvir/Velpatasvir Fixed Dose Combination in Participants With Chronic Hepatitis C Virus Infection Who Have Received a Liver Transplant</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>80</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-2104</other_id>
      <other_id>2016-000416-15</other_id>
    </other_ids>
    <first_received>May 20, 2016</first_received>
    <start_date>July 2016</start_date>
    <completion_date>June 2017</completion_date>
    <last_updated>August 26, 2016</last_updated>
    <last_verified>August 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>March 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Cessation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Percentage of Participants Who Permanently Discontinued Study Drug Due to any Adverse Event</outcome_measure>
      <outcome_measure>Percentage of Participants who Attain Sustained Virologic Response at 4 Weeks After Cessation of the Study Treatment Regimen (SVR4)</outcome_measure>
      <outcome_measure>Percentage of Participants who Have HCV RNA &lt; LLOQ by Visit While on Study Treatment</outcome_measure>
      <outcome_measure>Absolute and Change From Baseline/Day 1 in HCV RNA Through Week 12</outcome_measure>
      <outcome_measure>Percentage of Participants with Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Spain</country>
      <country>Switzerland</country>
      <country>United Kingdom</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02781571</url>
  </study>
  <study rank="3">
    <nct_id>NCT02722837</nct_id>
    <title>Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic Hepatitis C Virus Infection</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>120</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1522</other_id>
      <other_id>2015-003001-42</other_id>
    </other_ids>
    <first_received>March 24, 2016</first_received>
    <start_date>April 2016</start_date>
    <completion_date>March 2017</completion_date>
    <last_updated>July 19, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>December 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Participants with Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of Participants who Permanently Discontinue Study Drug Due to an Adverse Event</outcome_measure>
      <outcome_measure>Proportion of Participants with HCV RNA &lt; LLOQ at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of Participants with HCV RNA &lt; LLOQ on Treatment</outcome_measure>
      <outcome_measure>Change in HCV RNA From Day 1</outcome_measure>
      <outcome_measure>Proportion of Participants with Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Russian Federation</country>
      <country>Sweden</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02722837</url>
  </study>
  <study rank="4">
    <nct_id>NCT02671500</nct_id>
    <title>Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Participants With Chronic HCV</title>
    <recruitment open="Y">Recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>360</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1518</other_id>
    </other_ids>
    <first_received>January 29, 2016</first_received>
    <start_date>April 2016</start_date>
    <completion_date>December 2017</completion_date>
    <last_updated>July 12, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>September 2017</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of Participants with Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)</outcome_measure>
      <outcome_measure>Proportion of Participants who Permanently Discontinue Study Drug due to an Adverse Event</outcome_measure>
      <outcome_measure>Proportion of Participants with HCV RNA &lt; LLOQ at 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of Participants with HCV RNA &lt; LLOQ on Treatment</outcome_measure>
      <outcome_measure>Change in HCV RNA From Day 1</outcome_measure>
      <outcome_measure>Proportion of Participants with Virologic Failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>Malaysia</country>
      <country>Singapore</country>
    </unique_countries>
    <unique_states country="United States"/>
    <url>https://ClinicalTrials.gov/show/NCT02671500</url>
  </study>
  <study rank="5">
    <nct_id>NCT02480712</nct_id>
    <title>Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection</title>
    <recruitment open="N">Completed</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 3</phase>
    </phases>
    <enrollment>107</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1202</other_id>
    </other_ids>
    <first_received>June 22, 2015</first_received>
    <start_date>July 2015</start_date>
    <completion_date>June 2016</completion_date>
    <last_updated>July 5, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>April 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of study treatment (SVR12)</outcome_measure>
      <outcome_measure>Incidence of any adverse events leading to permanent discontinuation of study drug</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ at 4 and 24 weeks after discontinuation of study treatment (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on treatment</outcome_measure>
      <outcome_measure>HCV RNA change from Baseline/Day 1</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
      <outcome_measure>Proportion of participants that maintain HIV-1 RNA &lt; 50 copies/mL while on HCV treatment</outcome_measure>
      <outcome_measure>Serum creatinine change from baseline at the end of treatment and at Posttreatment Week 12</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
    </unique_countries>
    <unique_states country="United States">
      <state>Alabama</state>
      <state>Arizona</state>
      <state>California</state>
      <state>Georgia</state>
      <state>Illinois</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Ohio</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02480712</url>
  </study>
  <study rank="6">
    <nct_id>NCT02300103</nct_id>
    <title>Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study</title>
    <recruitment open="N">Active, not recruiting</recruitment>
    <study_results>No Results Available</study_results>
    <conditions>
      <condition>Hepatitis C Virus Infection</condition>
    </conditions>
    <interventions>
      <intervention type="Drug">SOF/VEL</intervention>
      <intervention type="Drug">RBV</intervention>
    </interventions>
    <sponsors>
      <lead_sponsor>Gilead Sciences</lead_sponsor>
    </sponsors>
    <gender>Both</gender>
    <min_age>18 Years</min_age>
    <age_groups>
      <age_group>Adult</age_group>
      <age_group>Senior</age_group>
    </age_groups>
    <phases>
      <phase>Phase 2</phase>
    </phases>
    <enrollment>150</enrollment>
    <funded_bys>
      <funded_by>Industry</funded_by>
    </funded_bys>
    <study_types>Interventional</study_types>
    <study_designs>
      <study_design>Endpoint Classification: Safety/Efficacy Study</study_design>
      <study_design>Intervention Model: Single Group Assignment</study_design>
      <study_design>Masking: Open Label</study_design>
      <study_design>Primary Purpose: Treatment</study_design>
    </study_designs>
    <other_ids>
      <other_id>GS-US-342-1553</other_id>
    </other_ids>
    <first_received>November 20, 2014</first_received>
    <start_date>December 2014</start_date>
    <completion_date>September 2016</completion_date>
    <last_updated>July 29, 2016</last_updated>
    <last_verified>July 2016</last_verified>
    <firstreceived_results_date>No Study Results Posted</firstreceived_results_date>
    <primary_completion_date>July 2016</primary_completion_date>
    <outcome_measures>
      <outcome_measure>Proportion of participants with sustained virologic response 12 weeks after discontinuation of therapy (SVR12)</outcome_measure>
      <outcome_measure>Incidence of adverse events leading to permanent discontinuation of study drug(s)</outcome_measure>
      <outcome_measure>Proportion of participants with sustained virologic response 4 and 24 weeks after discontinuation of therapy (SVR4 and SVR24)</outcome_measure>
      <outcome_measure>Proportion of participants with HCV RNA &lt; LLOQ on-treatment</outcome_measure>
      <outcome_measure>HCV RNA change from baseline</outcome_measure>
      <outcome_measure>Proportion of participants with virologic failure</outcome_measure>
    </outcome_measures>
    <unique_countries>
      <country>United States</country>
      <country>Australia</country>
      <country>New Zealand</country>
      <country>Puerto Rico</country>
    </unique_countries>
    <unique_states country="United States">
      <state>California</state>
      <state>Colorado</state>
      <state>Florida</state>
      <state>Maryland</state>
      <state>Massachusetts</state>
      <state>New Jersey</state>
      <state>New York</state>
      <state>North Carolina</state>
      <state>Pennsylvania</state>
      <state>Rhode Island</state>
      <state>Tennessee</state>
      <state>Texas</state>
      <state>Virginia</state>
    </unique_states>
    <url>https://ClinicalTrials.gov/show/NCT02300103</url>
  </study>
</search_results>
